Rip Enbrel derm

[anonymous]

It is important to note that OTEZLA continues to lead all other therapies in new to brand share, with approximately 40% in both psoriasis and PsA [psoriatic arthritis]. Additionally, OTEZLA total market share in the large psoriasis market has surpassed Enbrel and now stands at 21% of the total branded market.

 

[anonymous]

that was fast.

Otelza was approved for PsO only in Sepetember 2014!

In less than 1.5 years, it overtook Enbrel in total share!

 

[anonymous]

that was fast.

Otelza was approved for PsO only in Sepetember 2014!

In less than 1.5 years, it overtook Enbrel in total share!

Enbrel sucks and has sucked since Humira came to market in 2008

 

[anonymous]

See slide 25

http://files.shareholder.com/downlo...7EB9D7/Q4_2015_EPS_Deck_-_FINAL_-_1.28.16.pdf


Enbrel had 30% market share in April 2014, now it's 15%. We lost half our share in a little over a year in a half.

Unbelieveable. Humira share and Stelara only lost 2-4% share. We lost 15%!

Enbrel fucking blows asss

 

[anonymous]

See slide 25

http://files.shareholder.com/downlo...7EB9D7/Q4_2015_EPS_Deck_-_FINAL_-_1.28.16.pdf


Enbrel had 30% market share in April 2014, now it's 15%. We lost half our share in a little over a year in a half.

Unbelieveable. Humira share and Stelara only lost 2-4% share. We lost 15%!

Enbrel fucking blows asss

This is crazy. In 11 months from the PsO launch, Otezla overtook Enbrel in market share. We couldn't even hold on for a whole year.


Otelza launch is better than Repatha, Kyprolis, Blincyto, Imygic and Corlanor combined in its first full year. They made close to $500M in its first full year on market.

Amgen truly can't market unless they have monopoly products.

 

[anonymous]

we will need to raise Enbrel's price to 1 billion dollars now!

 

[anonymous]

With new sales and marketing leadership in place the quarterly Derm share loss is now double what it was just a year ago during the Otezla launch

 

[anonymous]

Enbrel for Derm is a terrible choice. Has been for a couple of years now. I used to try to sell etn to docs. Product is a waste of time unless it's rheum. Good luck, sheeple. Haha!

 

[anonymous]

With new sales and marketing leadership in place the quarterly Derm share loss is now double what it was just a year ago during the Otezla launch

Yep - INBU is full of losers in TO. By end of Q2, Enbrel will be at 10% derm share and at the end of the year it will sit at 5%. By next year, it will be down to 2% and more layoffs compounded by shitty Repatha sales fueling the flame. Every product that Amgen touches with competitive agents in the market goes to DIE!

 

[anonymous]

Yep - INBU is full of losers in TO. By end of Q2, Enbrel will be at 10% derm share and at the end of the year it will sit at 5%. By next year, it will be down to 2% and more layoffs compounded by shitty Repatha sales fueling the flame. Every product that Amgen touches with competitive agents in the market goes to DIE!

Bob Broadway can only cut so much. He fails to bring in new revenue $$ then investors will want his head.

Prepare for more layoffs and merging with another loser biotech

 

[anonymous]

Bob Broadway can only cut so much. He fails to bring in new revenue $$ then investors will want his head.

Prepare for more layoffs and merging with another loser biotech

amgen sucks

 

[anonymous]

The poster above is NUTS I'm over him or her.

 

[anonymous]

The poster above is NUTS I'm over him or her.

Have some Amgen koolaid. If you don't drink it, you will never be promoted.